Last reviewed · How we verify
Dementia associated with Parkinson's Disease — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Exelon | Exelon | US Department of Veterans Affairs | Acetylcholinesterase, Cholinesterase, Acetylcholine receptor subunit epsilon | |||
| Exelon | rivastigmine | Novartis | Acetylcholinesterase, Cholinesterase, Acetylcholine receptor subunit epsilon |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Novartis · 1 drug in Dementia associated with Parkinson's Disease
- US Department of Veterans Affairs · 1 drug in Dementia associated with Parkinson's Disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Dementia associated with Parkinson's Disease:
- Dementia associated with Parkinson's Disease treatment updates — RSS
- Dementia associated with Parkinson's Disease treatment updates — Atom
- Dementia associated with Parkinson's Disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Dementia associated with Parkinson's Disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/dementia-associated-with-parkinson-s-disease. Accessed 2026-06-10.
Related
- Dementia associated with Parkinson's Disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing